Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes 1. This highlights a broad need for support across both types of diabetes for insulin therapy optimization.
This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario †,2 for people on insulin through the following programs:
Ontario Drug Benefit (ODB) – for eligible residents on insulin aged 65+ or earlier if they:
Live in a long-term care home, home for special care, or Community Home for Opportunity
Are 24 or under without private insurance (OHIP+)
Receive professional home and community care
Get benefits from Ontario Works or ODSP
Are enrolled in the Trillium Drug Program
Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet the eligibility criteria.
Private Insurance – most private insurance plans cover Dexcom G7 for anyone on insulin.
– for eligible First Nations and Inuit clients on insulin.
'This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom's life-changing CGM technology,' says André Côté, Vice President and General Manager of Dexcom Canada. 'By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists ‡, 3 for the management of insulin-using patients.'
Dexcom G7 is the most accurate CGM with clinically proven outcomes §,2 including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes 4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin.
'As an endocrinologist, I've seen firsthand how continuous glucose monitoring has transformed diabetes management,' says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. 'Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical.'
Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time.
Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle:
Predictive Urgent Low Soon || alert that can warn in advance of severe hypoglycemia 9
Delay 1 st High alert after a meal that may help reduce insulin stacking 10,11
Waterproof sensor ¶
Fast 30-minute sensor warm-up time
Multiple sensor wear locations #
Direct to Apple Watch functionality ** – user can see glucose numbers right on their wrist
As the #1 patient recommended CGM in Canada ††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management.
To learn more about Dexcom G7 and the public and private coverage options available, please visit dexcom.com.
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.
Category: IR
_______________________________________
* For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit https://www.dexcom.com/en-CA/coverage/ontario-provincial-cgm-coverage.
† Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions.
‡ Based on a survey of Canadian Endocrinologists (n=41)
§ When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen.
|| Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes.
¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed.
# Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old.
** Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch.
†† Based on a comparison in NPS scores across major CGM brands
1 https://www.diabetes.ca/getmedia/b4f2add1-c56b-48e5-93cd-beb9feebb667/2024-Backgrounder-Ontario.pdf
2 Dexcom, data on file, 2025
3 Q&A, Dexcom Canadian Endos Report Wave 1 2024
4 Beck, RW, et al. JAMA. 2017;317(4):371-378.
5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
6 Martens T, et al. JAMA. 2021;325(22):2262-2272.
7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
9 Dexcom G7 User Guide.
10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255.
11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158.
12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10201853. About RadNet, Inc. RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800
New York Post
19 hours ago
- New York Post
Newborn dies after using home-birthing pool promoted by Instagram influencer
A newborn baby died after her mother delivered her using a home-birthing pool hired from 'freebirth' Instagram influencer Emily Lal, a coroner has found. The findings made in the Coroners Court of Victoria say it is 'unlikely' the baby girl would have died had she been born in a hospital setting, or if the home birth had occurred with appropriate midwife support. The mother, referred to as Ms. E, gave birth to her child in December 2022. A newborn died after a home-birthing pool hired from 'freebirth' Instagram influencer Emily Lal. ink drop – Prior to the birth, Ms. E contacted Lal – who operates as The Authentic Birthkeeper on Instagram – to rent a birthing pool to help deliver her baby. 'We aren't sure if she's breathing' The Melbourne-based influencer described herself as being 'disillusioned with the medical system', and held the 'philosophy' that registered midwives were 'complicit in, and contributing to, the harm of women'. The coronial inquest found Ms. E contacted the influencer to hire a birthing pool. According to the findings, Ms. E said she kept in contact with Lal 'socially' but did not seek any service or advice from the influencer. However, Ms. E said she requested to keep in contact with the influencer after the birth to 'conduct a post-partum visit'. Half an hour after Ms. E gave birth to her child, she sent a message to Lal saying 'I did it'. She was unable to deliver the placenta until the next morning. The morning following the birth, Ms. E realized something was wrong with her baby. Ms. E sent a message to Lal at about 8am saying, 'We can't wake her, we aren't sure if she's breathing,' with a picture of the baby, whose face had turned blue. Lal didn't see the message for 25 minutes, according to the inquest findings. The child was born in 2022 to her mother, who has been referred to as Ms. E. IdeaBug, Inc. – 'She was a healthy baby' Upon seeing the message, Lal made a Facetime call and saw the baby girl. Believing her to be dead, she told Ms. E and Mr. E to call for an ambulance. Paramedics noted the baby's heartbeat was flatlining and attempted CPR for 30 minutes, but were unable to revive her. Ms. E was transported to the Mercy Women's Hospital for treatment. Forensic pathologist Yeliena Baber said had Ms. E given birth in the hospital, preventive measures would have been put in place. Dr. Baber concluded: 'If Baby E was born in hospital and Ms. E had received appropriate antenatal care, it is highly unlikely that Baby E would have died, as she was a healthy baby and her death was caused by the prolonged delivery in a home birthing pool'. She further noted if a trained midwife had been present during the homebirth and prolonged labor, it would be expected they would escalate care to a hospital if 'it was clear that the baby was in distress'. Coroner Catherine Fitzgerald found Baby E's death was preventable. In her findings, she said the baby's death was 'unlikely to have occurred if the birth occurred in a hospital setting' and may have been avoided if the 'birth was a planned homebirth with appropriate midwife support'. 'A homebirth is distinguished from a 'freebirth', which is when someone chooses to birth their baby without medical or midwifery assistance,' she said. 'The publicly available information regarding water birth … are not directed at women intending to birth at home with no medical assistance or antenatal medical management.' 'The single consultation with (Ms. E's GP) late in the pregnancy provided no real opportunity for education to be given regarding birth options.' Fitzgerald did not make any adverse findings against the baby's parents or Lal.
Yahoo
a day ago
- Yahoo
Why LifeStance Health Group (LFST) Stock Is Up Today
What Happened? Shares of behavioral health company LifeStance Health (NASDAQ:LFST) jumped 11% in the afternoon session after the company reported mixed second-quarter 2025 results, delivering an earnings beat and a full-year profit forecast that topped Wall Street estimates. The mental healthcare provider's revenue for the quarter grew 10.6% year-over-year to $345.3 million, which was in line with analyst forecasts, driven by a 10.7% increase in sales volumes. On the bottom line, the company demonstrated improved profitability, posting a GAAP loss of $0.01 per share. This marked a significant improvement from the $0.06 per-share loss in the same period last year and beat consensus estimates for a $0.03 loss. Looking ahead, management provided a full-year Adjusted EBITDA forecast with a midpoint of $145 million, above analyst expectations. However, the company's revenue guidance for the next quarter came in below estimates, creating a mixed picture for investors. Is now the time to buy LifeStance Health Group? Access our full analysis report here, it's free. What Is The Market Telling Us LifeStance Health Group's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. But moves this big are rare even for LifeStance Health Group and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 21 days ago when the stock dropped 4% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. LifeStance Health Group is down 42.6% since the beginning of the year, and at $4.33 per share, it is trading 47% below its 52-week high of $8.17 from January 2025. Investors who bought $1,000 worth of LifeStance Health Group's shares at the IPO in June 2021 would now be looking at an investment worth $197.77. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
